



Adherence and Disclosure

Challenges for Adolescents Living with HIV

Juliet Houghton
Programme Director
CHIVA South Africa



CHIVASOUTHAFRICA
MENTORING. PARTNERING. SAVING LIVES.

Key Principles

- Adherence and disclosure intrinsically linked
- Need to build a body of knowledge in the growing child – foundations for a healthy adolescence and adulthood
- Conversations with adolescents also need to be cognitively and developmentally appropriate





CHIVASOUTHAFRICA
MENTORING. PARTNERING. SAVING LIVES.

Disclosure

Two key aspects of disclosure that affect adolescents with HIV:-

1. Learning their own diagnosis
2. Onward disclosure to family, friends, partners, employers etc





CHIVASOUTHAFRICA
MENTORING. PARTNERING. SAVING LIVES.

The Evidence

Positive outcomes of disclosure include:-

- promotion of trust (family and healthcare staff)
- improved access to support services
- better adherence
- improved family communication
- improved mental and physical health ¹⁻⁷
- however, other literature suggests negative outcomes of disclosure ⁸



CHIVASOUTHAFRICA
MENTORING. PARTNERING. SAVING LIVES.

The Evidence

Our understanding has also changed:-

- Growth of child/youth rights movement
- Survival of HIV-infected children into adolescence and adulthood
- Need for long-term adherence to ART
- Cognitive development of children that demonstrates understand concepts such as 'illness and 'death' ^{3, 9 – 11}





CHIVASOUTHAFRICA
MENTORING. PARTNERING. SAVING LIVES.

Disclosure Cont ...

Disclosure presents particular challenges to health workers, including:-

not sure what to say

not sure how to say it

not sure what they already know

not sure what the right answers are

fear of upsetting adolescent

fear of upsetting caregivers/partners

fear of defaulting healthcare



CHIVA SOUTH AFRICA
MENTORING. PARTNERING. SAVING LIVES.

Disclosure Cont ...

The reality is that:-

- saying nothing is often worse than saying something badly
- we need to ascertain what is already known – this is often more than health workers think!
- build our own knowledge and skills
- by sharing knowledge we can improve confidence, knowledge and skills of adolescents
- retention in care is improved if clients understand why they are attending



CHIVASOUTHAFRICA
MENTORING. PARTNERING. SAVING LIVES.

When and How to Disclose

- In vertically infected children, disclosure should have occurred prior to adolescence!
- A process not an event?
- Avoid ‘disclosure of diagnosis’ – negative
- Prefer ‘discussing’ or ‘sharing’ HIV status
- ‘Confirmation of knowledge’ – elicits baseline knowledge



CHIVASOUTHAFRICA
MENTORING. PARTNERING. SAVING LIVES.

Disclosure Cont

- Health workers have a pivotal role in supporting families to disclose
- Not enough to tell them it is important that they do it – needs a partnership
- Have we made HIV ‘special’ again?
- Need to promote benefits of informing children and adolescents





Disclosure of HIV Status and Adherence to Daily Drug Regimens Among HIV-Infected Children in Uganda ¹²

Bikaako-Kajura et al, online pub 22 June 2006, Springer Science + Business Media Inc.

<http://link.springer.com/article/10.1007%2Fs10461-006-9141-3?LI=true>

CHIVA SOUTH AFRICA
MENTORING. PARTNERING. SAVING LIVES.

- In-depth interviews with 42 children taking ART +/- CTX
- Complete disclosure of HIV status and strong parental relationships were related to good adherence
- Structural factors including poverty and stigma were barriers to adherence even for children who had complete disclosure and a supportive relationship with a parent

Disclosure Type	Missed doses			
	Never	Occasionally	Frequently	Total (%)
Complete parental disclosure	8	4	-	12 (29)
Non-disclosure	3	8	3	14 (33)
Partial disclosure	1	5	10	16 (38)



CHIVASOUTHAFRICA
MENTORING. PARTNERING. SAVING LIVES.

Adherence

- Adherence in adolescents is more challenging than children and adults
- Adherence wanes over time
 - Week 48, only 27.3% of adolescents were virologically suppressed (SA)¹³
 - Week 48, 50% less likely to maintain adherence and 70% less likely to achieve virological suppression when compared to adults (SSA)¹⁴
 - Only 62% of adolescent respondents indicated adhering 95% of the time (UK national survey)¹⁵



Adherence - Challenges

- Often highly treatment experienced
- Drug resistance
- Maintaining life long treatment
- Preserving future drug options

Increased drug resistance seen in paediatrics with 91% of virologically failing children having drug resistance (SA study)¹⁴

21% of adolescent patients in a London clinic already had dual class resistance¹⁷



The Evidence

- Prospective studies in adults and children have demonstrated the risk of virological failure increased in proportion to the number of missed doses¹⁶⁻²⁰
- Long term adherence for vertically infected adolescents is particularly challenging²¹⁻²³
- Poor school attendance, alcohol or drug abuse, depression and advanced disease are correlated with non-adherence²³
- Pill counts, pill trays, pharmacy checks and self-reporting of missed doses all useful strategies to assess adherence^{17, 20-23}
- Cell phone reminders also successful intervention for adolescents on ART²⁴



CHIVASOUTHAFRICA
MENTORING. PARTNERING. SAVING LIVES.

Adherence in Adolescents

- Increasing independence – self identity
- Peer pressure/preference
- Increasing autonomy and self-reliance
- Physiological and psychological growth and development
- Long term side effects – body image
- Transition to adult services
- Transition from adult-focused communications to the YP



Interventions

- Assess adherence in a way that empowers the adolescent – non-critical (holistic)
- Ensure adolescents understand why they need to adhere
- Assist adolescents to fit ARV's into their lifestyle and not the other way round
- Privacy and confidentiality
- Provide youth-friendly services – one stop
- Support– peer and professional
- Novel technologies – Mxit (i.e. cell-life; HIV 360)
- Good communication



Opportunities

- Adolescence is a time of opportunity and threat
- Know your population
- Improving knowledge of HIV/health and rationale of interventions should assist adherence
- Our role is crucial: open, non-judgmental attitude, welcoming environment, holistic care
- To interrupt ART? Research vs real world
- Peer support can be a powerful intervention – can also reduce burden on staff
- We can communicate without using the idioms!





www.pozitude.co.uk/apps

Phone Apps

To help you remember to take your medication we've developed a smart phone app. The idea behind it is that it will remind you to take your medication on the days, and at the time you need to take them. Then once you've taken them you can add them to a chart to keep track of when you've taken them.

We've even added a hospital appointments section so you can be reminded to go to the doctor or hospital.

[To download the iPhone iDiary app click here](#)

[To download the Android iDiary app click here](#)

[To download the Blackberry iDiary app click here](#)

While we've tried our best to make sure that everyone can access the apps, unfortunately due to the phone company limitations we can only supply the app to iPhones with an iOS 4.3 or greater and Blackberry OS 7 (you also need a SD card).

Once downloaded please leave your reviews if you like the app!



CHIVA SOUTH AFRICA
MENTORING. PARTNERING. SAVING LIVES.

Conclusions

- Good communication a key component of successful disclosure (primary and onward)
- Also essential for adherence
- Knowledge empowers adolescents to make informed choices
- Establishing and maintaining supportive relationships with adolescents increases adherence, retention in services and improves long-term outcomes
- Holistic approach crucial (i.e. HIV, school/work, relationships and SRH)
- Wealth of resources available to assist



CHIVA SOUTH AFRICA
MENTORING. PARTNERING. SAVING LIVES.

Conclusions

- Adolescents can be difficult, frustrating, challenging, demanding, unreasonable, unreliable
- They can also be accommodating, entertaining, supportive, giving, responsible
- Often the greatest barriers to working successfully with adolescents is our own fears and anxieties about the areas we need to address with them (most notably sexuality and sexual health)
- Communication underpins all interventions
- As providers, we need to

Say what we mean



... and mean what we say!





Acknowledgments

- National Department of Health Adolescent Working Group
- National Department of Health HIV Disclosure Working Group
- Alice Armstrong – Adolescent Coordinator, CHIVA South Africa
- Zameka Sobantu – Programme Coordinator, CHIVA South Africa
- Paediatric and adolescent volunteers of CHIVA South Africa
- All the young people who have taught me so much over the last 20 years



CHIVASOUTHAFRICA
MENTORING. PARTNERING. SAVING LIVES.

Thank you for your attention

www.chiva-africa.org





CHIVASOUTHAFRICA
MENTORING. PARTNERING. SAVING LIVES.

Selected Resources

- Saranne Meyerfeld & Marnie Vuyovic. *Sexual and Reproductive Health for young HIV positive adolescents: The club concept in support groups*. Anova Health Institute 2011
- WHO 2010. *IMAI One-day Orientation on Adolescents Living with HIV: Participants Manual*
- WHO 2010. *Adolescent Job Aid: A handy desk reference tool for primary level health workers*
- Pathfinder International 2004. *Certification tool for youth friendly services*. Can be found at http://www.pathfind.org/Publications_RH_Resources_ASRH
- *Rapid Assessment Tool for Sexual & Reproductive Health and HIV Linkages: A Generic Guide*. Prepared and published by IPPF, UNFPA , WHO, UNAIDS, GNP+, ICW and Young Positives, 2009. Published in London, United Kingdom, September 2009
- www.chiva-africa.org Adolescent section with numerous free resources



CHIVASOUTHAFRICA
MENTORING. PARTNERING. SAVING LIVES.

References

1. American Academy of Pediatrics Committee on Pediatrics AIDS. Disclosure of illness status to children and adolescents with HIV infection. *Pediatrics* Jan;1999 103(1):164–166. [PubMed: 9917458]
2. Walker, G. In the midst of winter. New York: Norton; 1993. Wiener et al. Page 10 *J Dev Behav Pediatr*. Author manuscript; available in PMC 2008 June 26. NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author Manuscript
3. Lipson M. Disclosure of diagnosis to children with human immunodeficiency virus or acquired immunodeficiency syndrome. *J Dev Behav Pediatr* Jun;1994 15(3):S61–65. [PubMed: 8063922]
4. Funck-Brentano I. Informing a child about his illness in HIV infection: words and meaning. *Psychiatr Infant* 1995;38(1):109–139. [PubMed: 8559848]
5. Wiener, L.; Septimus, A.; Grady, C. Psychosocial Support and Ethical Issues for the Child and Family. In: Pizzo, P.; Wilfert, K., editors. *Pediatric AIDS: The challenge of HIV infection in infants, children, and adolescents*. 3. Baltimore, MD: Williams and Wilkins; 1998. p. 703-727.
6. Mellins CA, Brackis-Cott E, Dolezal C, et al. Patterns of HIV Status Disclosure to Perinatally HIV Infected Children and Subsequent Mental Health Outcomes. *Clinical Child Psychology and Psychiatry* 2002;7(1):101–114.
7. Ng, WYK.; Mellins, CA.; Ryan, S. The mental health treatment of children and adolescents perinatally infected with HIV. In: Abrams, E., editor. *Topic of the month*. 2004.
8. New, M.; Lee, S.; Pao, M. Prevalence of mental health in pediatric HIV: a family perspective. Presented at the NIMH Conference on the Role of Families in Preventing and Adapting to HIV/AIDS; Washington, DC. 2003.



CHIVASOUTHAFRICA
MENTORING. PARTNERING. SAVING LIVES.

References

9. Gaylin, W.; Macklin, R., editors. Who speaks for the child? The problems of Proxy Consent. New York, NY: Plenum Press; 1982.
10. Bibace R, Walsh ME. Development of children's concepts of illness. *Pediatrics* Dec;1980 66(6):912–917. [PubMed: 7454481]
11. Spinetta J, Maloney J. Death anxiety in the outpatient leukemic child. *Pediatrics* 1975;56:1034–1037.
12. Bikaako-Kajura et al Disclosure of HIV Status and Adherence to Daily Drug Regimens Among HIV-Infected Children in Uganda. Online pub 22 June 2006, Springer Science + Business Media Inc. <http://link.springer.com/article/10.1007%2Fs10461-006-9141-3?LI=true>
13. Nglazi MD et al. Treatment outcomes in adolescents attending a community based antiretroviral therapy clinic in South Africa. 5th South African AIDS Conference, Durban 2011.
14. Thomas WN. Resistance mutations and their clinical relevance in HIV-infected children started on a protease inhibitor based regimen. 5th South African AIDS Conference, Durban 2011
15. McDonald S. *Young people and self-reported adherence to antiretroviral therapy: a HYPNet survey*. 17th annual British HIV Association conference: Bournemouth, abstract P198, 2011
16. Ferrand R, Miller R, Jungmann E. Management of HIV Infection in adolescents attending inner London HIV services. *International Journal of STD & AIDS* 2007;18:633-634.
17. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. *Ann Intern Med* 2000;133:21-30.) Pathfinders International. Increasing HIV/AIDS Therapy Adherence among Youth in Mozambique: The TAP/Pathfinder International Experience. Maputo: Pathfinders International; 2009



CHIVASOUTHAFRICA
MENTORING. PARTNERING. SAVING LIVES.

References

18. Flynn PM, Rudy BJ, Douglas SD, et al. And Pediatric AIDS Clinical Trial Group 381 Study Team. Virologic and immunologic outcomes after 24 weeks in HIV type 1-infected adolescents receiving highly active antiretroviral therapy. *J Infect Dis* 2004;190:271-279.
19. Howard AA, Arnsten JH, Lo Y, et al. Prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women. *AIDS* 2002;16:2175-2182.
20. Murphy DA, Sarr M, Durako SJ, et al. Adolescent Medicine HIV/AIDS Research Network. Barriers to HAART adherence among human immunodeficiency virus-infected adolescents. *Arch Pediatr Adolesc Med* 2003;157:249-255.
21. Belzer ME, Fuchs DN, Luftman GS, Tucker DJ. Antiretroviral adherence issues among HIV-positive adolescents and young adults. *J Adolesc Health* 1999;25:316-319.
22. Murphy DA, Belzer M, Durako SJ, et al. Adolescent Medicine HIV/AIDS Research Network. Longitudinal antiretroviral adherence among adolescents infected with human immunodeficiency virus. *Arch Pediatr Adolesc Med* 2005;159:764-770
23. Chadwick EG, Rodman JH, Britto P, et al., PACTG Protocol 345 Team. Ritonavir-based highly active antiretroviral therapy in human immunodeficiency virus type 1-infected infants younger than 24 months of age. *Pediatr Infect Dis J* 2005;24:793-800.
24. Warren A Kaplan . Debate: Can the ubiquitous power of mobile phones be used to improve health outcomes in developing countries? *Globalization and Health* 2006, 2:9 doi:10.1186/1744-8603-2-9 Available from: <http://www.globalizationandhealth.com/content/2/1/9>